Sector News

Rooting for pharma's deal volume to reach 2015's heights?

October 31, 2016
Life sciences

Remember 2015, when pharma was shattering deal-volume records? These days, it seems like a pretty long time ago.

In Q3, deal activity has headed south–both in volume and in value–compared with the year-ago quarter, according to PwC’s Global Pharma & Life Sciences Deals Insights Q3 2016 Update. And the decrease in value has been “considerable.”

The reason? Pharma hasn’t seen as many large deals–especially those greater than $1 billion. The industry registered just 7 in the quarter, with Pfizer’s $14.1 billion Medivation buy taking the cake.

And the reasons for that? They include potential interest rate movements and recent attention on drug pricing, which has brought an unwelcome spotlight on more than a few specialty players. As a result, potential acquirers are waiting “to see how this trend develops in the next few quarters,” the authors wrote.

As PwC notes, the recent M&A decline means “deal volumes in the future have the ability to trend upward.” But that doesn’t mean they will.

Instead, what’s more likely is that they’ll stay “depressed” until “uncertainty around general economic factors and industry conditions” are cleared up.

And even if deal volumes head upward again by the end of the year–an event that’s possible, PwC acknowledged, considering that companies including Valeant and Endo are currently assessing their portfolios–2016’s total deal value may still look low relative to prior years.

Potential acquirers are becoming “more disciplined with deal pricing” and scouting smaller targets.

If that shift in thinking doesn’t sound familiar, consider Allergan: After last year agreeing to technically buy Pfizer in a record-breaking $160 billion megadeal–later thwarted by the U.S. Treasury–Allergan recently committed itself to vastly smaller “stepping-stone deals,” as CEO Brent Saunders likes to call them.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach